advertisement
11.4 Prostaglandins (19)
Showing records 1 to 19
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins26043 Influence of geranylgeranylacetone on the expression of HSP70 in retina of rats with chronic IOP elevation
Liu Z-L; Wang Y-R; Sha Q; Nie Q-Z
International Journal of Ophthalmology 2010; 10: 413-416
25887 Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
Aihara M
Clinical Ophthalmology 2010; 4: 163-170
25840 Travoprost: A prostaglandin analogue for the treatment of glaucoma
Brooks TC; Burlingame M; Burk M; Tortorice K; Dong D; Glassman PA; Lynch JA; Good CB; Rickman HS; Claborn M
Formulary 2009; 44: 322-328
25921 Management of hypotrichosis of the eyelashes: Focus on bimatoprost
Fagien S
Clinical, Cosmetic and Investigational Dermatology 2010; 3: 39-48
25802 A meta-analysis of therapy comparison between bimatoprost and timolol in ocular hypertention eye
Ge Y; Wang L; Cheng J; Huang Z
Chinese Ophthalmic Research 2009; 27: 1120-1125
26217 Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface
Honda N; Miyai T; Nejima R; Miyata K; Mimura T; Usui T; Aihara M; Araie M; Amano S
Archives of Ophthalmology 2010; 128: 466-471
26206 Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension
Katz LJ; Cohen JS; Batoosingh AL; Felix C; Shu V; Schiffman RM
American Journal of Ophthalmology 2010; 149: 661-671
26101 The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost
Kraft ME; Glaeser H; Mandery K; König J; Auge D; Fromm MF; Schlötzer-Schrehardt U; Welge-Lüssen U; Kruse FE; Zolk O
Investigative Ophthalmology and Visual Science 2010; 51: 2504-2511
25873 Bimatoprost in the treatment of eyelash hypotrichosis
Law SK
Clinical Ophthalmology 2010; 4: 349-358
25692 Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel study
Smith S; Somogyi C; Beddingfield F; Whitcup S; Fagien S
Journal of the American Academy of Dermatology 2009; 60: AB8
26120 Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes
Wester ST; Lee WW; Shi W
Ophthalmology 2010; 117: 1024-1031
25759 Asymptomatic bradycardia possibly associated with travoprost therapy
Yamreudeewong W; Dell AA; Pulley KR; Stepp PD
Journal of Pharmacy Practice 2010; 23: 74-77
26122 Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% (Cosopt) on Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: A Prospective, 4-week, Open-label, Randomized, Co
Hatanaka M; Reis A; Sano ME; Susanna R Jr
Journal of Glaucoma 2010; 19: 331-335
25648 Advances in eicosanoid research, novel therapeutic implications
Haeggstrom JZ; Rinaldo-Matthis A; Wheelock CE; Wetterholm A
Biochemical and Biophysical Research Communications 2010; 396: 135-139
25828 A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost
Traverso CE; Ropo A; Papadia M; Uusitalo H
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 97-104
25721 Physicians treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma
Hahn SR; Kotak S; Tan J; Kim E
Current Medical Research and Opinion 2010; 26: 957-963
25841 Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective
Berenson K; Arora S; Kymes S; Hollander DA; Fiscella R; Burk C; Patel V
Journal of Managed Care Pharmacy 2010; 16: 146
25891 First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results
Schmier JK; Covert DW
Clinical Ophthalmology 2010; 4: 437-445
25822 Quantification of patient population impact of contra-indications: Glaucoma therapy
Maguire A; MacLachlan S
Pharmacoepidemiology and Drug Safety 2009; 18: S100
